Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in March (see “Takeda Pursuing Exosome Therapies Through Evox

Read the full 452 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE